Home / Transcripts / Alpha Cognition Inc. (ACOG) · May 14, 2026

Alpha Cognition Inc. (ACOG) Earnings Call Transcript

May 14, 2026

NASDAQ US Health Care Biotechnology earnings 35 min

Earnings Call Speaker Segments

Henry Du executive
#1

Thank you, Kate. Hello, everyone, and good afternoon — we appreciate you being here for Alpha Cognition's Q1 2026 conference call covering our financial results. A press release went out today after the market closed to announce these results. Joining me on this call are Michael McFadden, Alpha Cognition's Chief Executive Officer, and Lauren D'Angelo, our Chief Operating Officer. You can access today's call through the investors section of the company's website at www.alphacognition.com. While we speak, management might make certain forward-looking statements about future events and how the company will perform going forward; such forward-looking statements reflect Alpha Cognition's current perspective on existing trends and information. These forward-looking statements should not be viewed as guarantees of future performance and carry risks and uncertainties, including those described in the Risk Factors section of the company's latest SEC filings. Results actually achieved could differ materially from what these forward-looking statements project. For those of you who may be listening to the replay, this call is being held and recorded on May 14, 2026. The company may have made additional announcements related to the topics discussed since then. Please reference the company's most recent press releases and current filings with the SEC. Except as required by applicable securities laws, Alpha Cognition declines any obligation to update these forward-looking statements. I'll now turn the call over to Michael. Michael?

Michael McFadden executive
#2

Thank you, Henry Du. Good afternoon to all of you, and thanks for joining us on today's call. The period covering the first quarter of 2026 marks our fourth complete quarter of commercial activity for ZUNVEYL, which is the first novel oral therapy for Alzheimer's to gain approval in over 15 years, and it was a robust quarter. We achieved a 40% rise in revenue compared with the previous quarter, saw faster uptake among prescribers, and moved forward on key strategic goals throughout our clinical programs. Our intellectual property holdings were reinforced, and the company continued expanding its infrastructure as we move into the growth stage for ZUNVEYL. We keep executing with rigor and self-assurance, and in my view this quarter shows that the commercial path of ZUNVEYL is aligning nicely with what we anticipated internally; during Q1 2026, our net total product revenues reached $3.5 million, which is a 40% sequential gain compared with Q4 2025. Although we're quite happy with how ZUNVEYL is progressing, we remain at just the beginning of its commercial journey. The company stays hopeful and thinks we will keep observing evidence of durable product results and uptake in the long-term care sector. Examining Q1, we experienced growth during the quarter, with March producing our best month for demand sales, and April is outperforming March. On the whole, we think we are aligned with our 2026 strategic priorities, and we still anticipate reaching operating profitability in 2027. Regarding adoption, our prescription key performance indicators continue to be solid. The number of bottles we dispensed rose 23% compared with Q4. Our count of HCP writers increased 23% compared with the close of 2025, and we are on pace to hit our 2026 target of roughly 2,000 prescribers. The prescribers we call on expanded 93% from one quarter to the next, and our nursing homes holding ZUNVEYL prescriptions increased 25%. In addition, the commercial team assembled a 60-person customer-facing group during the quarter. We brought in and added seasoned marketing and payer engagement expertise to the team. During the previous month, we reinforced our board of directors by welcoming a new independent board member, Bethany Sensenig; we intend to draw on her background to assist in shaping Alpha Cognition's strategy and to have her deliver financial governance for the company. Shifting to our clinical programs, we currently have three active real-world studies in progress, which we think will bolster ZUNVEYL's standing with payers and healthcare providers. BEACON, our real-world effectiveness trial assessing ZUNVEYL among long-term care residents who have Alzheimer's disease, will finish enrollment during this quarter. The company will disclose top-line data from BEACON by no later than early Q3, which is sooner than our earlier expectation of late Q4. CONVERGE, our retrospective data analysis looking at tolerability, dosing, polypharmacy, and adverse events in long-term care, begins in Q2 as scheduled, and we anticipate top-line data from this trial in Q3 of 2026; we expect that both BEACON and CONVERGE will give the company many publication opportunities in the year ahead. RESOLVE, our Phase IV outpatient study, will likewise begin this quarter. This study will supply further data on tolerability and efficacy when treating behaviors tied to Alzheimer's disease in the outpatient setting. On the intellectual property side, the U.S. Patent Office granted two patents that offer added protection for ZUNVEYL. Back in February, we received a new patent that covers dosage regimens for benzgalantamine, and then in March, a second one was issued, this one covering how benzgalantamine is used to treat traumatic brain injury. Protection of the product now runs through 2045 under both patents, and by the way, the TBI market is an addressable opportunity for the company that we estimate at roughly $14 billion. Turning to our sublingual formulation program, a comparative pharmacokinetic study against our tablet will be started this quarter. If that PK data demonstrates equivalence, it may be enough to move the sublingual formulation forward into the clinic. As for our partnership outside the U.S., CMS Pharma keeps pushing the regulatory process forward in a number of countries throughout Asia, and we expect two strategic product approvals during 2026. Looking at things financially, operating spend for the company came in at about $12 million, which shows a deliberate investment in our commercial capabilities as well as in studies that back up our positioning with healthcare providers and payers. Let me be straightforward about how we view our investment phase. The net loss we posted this quarter reflects the company intentionally scaling our efforts. Capital is being deployed toward the opportunities in the business with the highest returns, and that includes widening prescriber reach, generating real-world evidence in support of ZUNVEYL, and opening up more payer access. Those investments are what will carry the company to operating profitability in 2027 and beyond. We stay on track with those targets. Henry is going to walk through the financials in detail now. Once Henry finishes his remarks, Lauren will give a comprehensive commercial update. Henry?

Henry Du executive
#3

Thanks, Michael, and good afternoon to all of you. I'll be going over what we achieved in the first quarter of 2026, and I'd encourage you to pull up the press release we issued today, as well as the 10-K and 10-Q that were filed this afternoon. In Q1 of 2026, ZUNVEYL generated total net product revenues of $3.5 million. For comparison, Q4 2025 net product revenues were $2.5 million, so that's a 40% increase on a sequential, quarter-over-quarter basis. On a year-over-year basis, Q1 net product revenues reached $347,000, reflecting only the final two weeks of March 2025 following our commercial launch, in addition to $2.6 million in licensing revenue tied to our CMS agreement. Looking at how we got from that initial quarter to $3.5 million in Q1 2026, you can see just how far ZUNVEYL has come commercially in a single year on the market. When you factor in cost of revenues, our total operating expenses for Q1 2026 landed at approximately $11.6 million. That figure speaks to the ongoing build-out of our commercial operation — a fully staffed customer-facing sales team of 60 people, stronger capabilities for engaging payers, marketing support, and the launch of our RESOLVE clinical study. To put those numbers in perspective, we spent $10.7 million on total operating expenses during Q4 2025, versus $6.3 million in Q1 of last year. Moving from those earlier quarters into Q1 2026, you can see the deliberate spending choices Michael walked through: growing the sales team, widening our commercial footprint, and kicking off trials designed to produce the real-world evidence required to speed up both payer reimbursement and physician uptake. During Q1 2026, our net loss came in at roughly $6.5 million, which works out to $0.30 basic loss per share, versus a net loss of $1.7 million, or $0.11 per share, for Q1 2025. That year-over-year widening stems from what we put into our commercial build-out, our work with payers, and our clinical initiatives — each of them essential to moving ZUNVEYL along its longer-term path. We're also getting better at running things efficiently at our core, and at this stage of growth, we think the amount we're investing right now makes sense. On March 31, 2026, we held roughly $54.2 million in cash and cash equivalents, down from $66 million on December 31, 2025. There's no debt on our balance sheet, and our view remains that the capital we have on hand is enough to keep operations running, support the continued commercialization of ZUNVEYL, move our clinical programs forward, and get us to operating profitability in 2027. We aren't offering revenue guidance right now, but we are reaffirming our full year 2026 operating expense guidance of approximately $54 million-$58 million. Our outlook hasn't shifted at all — we still anticipate a slight bump in Q2 expenditures compared with Q1, driven by RESOLVE scaling up and faster expansion of our peer-to-peer education initiatives. Across all of 2026, the spending trajectory continues to match what we laid out. In our view, that captures the funding required for commercial operations, 3 real-world clinical studies, payer engagement programs, and moving our sublingual formulation forward. At this point, I'll hand things over to Lauren for an update on the commercial side. Lauren?

Lauren D'Angelo executive
#4

Thanks, Henry. I want to walk you through a detailed picture of our commercial performance for Q1 2026. Over that quarter, we made substantial progress across multiple areas — getting prescribers on board, extending our reach into nursing homes, and deepening relationships with payers. The figures tell a strong story: our commercial momentum is both lasting and picking up speed. Starting with adoption, our commercial team connected with approximately 7,900 healthcare providers overall during Q1, and engaged about 3,762 prescribers — a 93% increase compared with the prior quarter. That expansion stems from the wider coverage provided by our 60-person customer-facing field team, which is now at full headcount. During the quarter, the count of HCP writers categorized as prescribers who had issued at least one ZUNVEYL prescription increased by 23% versus the prior quarter, hitting 1,060. Among the prescribers our sales team contacted, that translates to a conversion rate of about 28%, which we view as a strong indicator of early commercial efficiency. Our goal when 2026 started was to get to roughly 2,000 prescribers, and the Q1 growth we delivered keeps us solidly on pace to achieve it. Of those 1,060 active writers, 795, or about 75%, have issued prescriptions more than once. The key point is that this reflects not just initial uptake but ongoing utilization, because on average each writer generated about five to six prescriptions across the quarter. Homes with ZUNVEYL prescriptions totaled 914, up 25% from the previous quarter. That works out to roughly 36% penetration for the facilities we reached out to, and every active home was filling an average of over six prescriptions during the quarter. Repeat orders have come from 736 of them — an 81% repeat rate when you look at it by facility. That's the signature of adoption that sticks. In Q1, we reached out to 2,502 unique nursing homes, up 26% from Q4, and March by itself brought 110 new homes on board — the biggest single-month haul of new accounts since we launched. The month-by-month path in Q1 stands out, since it shows how our commercial momentum gathered strength as the quarter went on. March saw us move 2,321 bottles — a record for demand since we launched. That's up about 29% from February, and it gives us a solid exit velocity heading into Q2. For Q1 overall, we dispensed 6,054 bottles, which is 23% higher than the 4,941 bottles in Q4. Looking at both prescribers and facilities, what we're seeing are consistent patterns of depth, not just breadth, when it comes to adoption. Conversion rates, repeat utilization, and prescriptions per account all indicate a product that isn't merely being tried — it's being actively integrated into clinical practice. We think our ongoing real-world evidence programs will reinforce these adoption trends over time. The way BEACON, CONVERGE, and RESOLVE were built, they aim to produce data that matters clinically, gathered in the real-world environments where people with Alzheimer's receive treatment — that covers long-term care as well as outpatient practice. A key point is that our commercial team should get solid promotional benefit from these trials, since they will back peer-to-peer education, give us stronger footing in conversations with payers, and help physicians feel more confident when it comes to tolerability, managing polypharmacy, behavioral outcomes, and the burden on caregivers. As we keep widening market access and driving more prescriber utilization, we see these datasets taking on greater importance as tools. Also during the quarter, we put through a price increase of 6% on ZUNVEYL, bringing it to $869.36. Our capacity to implement price increases, we think, mirrors rising assurance regarding what the product offers, robust demand momentum beneath the surface, and the deepening uptake we continue to observe among both those writing prescriptions and the facilities themselves. On the payer side, access stands as our biggest short-term obstacle as well as our biggest short-term chance. Because our prescription growth and repeat-use patterns remain so solid, we see this as a matter of timing rather than any limitation on demand. Throughout Q1, our team stayed actively engaged with both national and regional health plans. For some context on our current position, we hold Medicare Part D agreements with 2 large PBMs, which together cover roughly 45 million lives. Neither of those contracts imposes prior authorization rules for ZUNVEYL. From a policy perspective, that puts us in a good spot once implementation widens across plans further downstream. Right now, implementation among downstream plan clients sits at about 16% of the entire contracted book of business. In cases where our reimbursement team assists with the prior authorization filing process, we see an approval rate of about 89%. Getting to wider implementation amounts to a wait-and-see situation, which is typical for an access curve. As often happens with therapies that have just launched, plans watch early utilization patterns before they switch on formulary access fully throughout their networks; we anticipate contracts starting to gain meaningful momentum during Q2 and Q3, and we're trying to speed that up via our real-world evidence initiative and our enlarged payer engagement team; we're noticing modest improvements in certain plans and regions, and our current priority is turning those initial wins into wider, system-level adoption among big national plans. A full sales force of 60 customer-facing representatives plus management is now hired and producing results. Now that the team is completely deployed, our attention is on boosting productivity and conversion efficiency in every territory. Beyond that, we're applying AI-powered commercial analytics and targeting solutions to sharpen how territories are executed, identify prescribers with high potential value, and make our field engagement efforts more efficient. Our expectation is that these capabilities will allow the commercial team to expand in a disciplined manner while extracting maximum value from each dollar we invest. In the first quarter, we wrapped up speaker training with 48 key opinion leaders and began a gradual rollout of our peer-to-peer education program, which is an essential tool for converting prescribers who are still exploring into confident ZUNVEYL prescribers. During April, we presented new clinical findings at the American Association for Geriatric Psychiatry conference, and in May we'll be appearing at the Neuroscience Education Institute Spring Congress. Those engagements are hugely important to how we build clinical confidence and raise awareness with high-value prescribers. Together with our virtual webinar series and digital education programs, these conference appearances represent a comprehensive multi-channel effort aimed at earning scientific credibility and prescriber trust for ZUNVEYL. In summary, Q1 2026 brought deliberate, well-executed commercial progress; we're seeing strong underlying demand, higher repeat utilization, and growing depth of adoption across both prescribers and facilities. We're enlarging our prescriber base, increasing facility penetration, assembling a persuasive evidence foundation, and achieving consistent headway on payer access. With availability growing, we think these basics put us in a strong spot for ongoing acceleration. At this point I'll pass things back over to Michael for some final comments.

Michael McFadden executive
#5

Thank you, Lauren. Let me quickly go over what I see as the main takeaways for the company in Q1 2026. To start, ZUNVEYL is expanding. From Q4 to Q1, we achieved 40% sequential revenue growth, and March gave us our largest bottle count since launch. Growth continues, and our commercial momentum is speeding up. Second, our clinical programs are moving forward faster than planned. Enrollment in BEACON wraps up during this quarter. Top-line data should be reported by early Q3 at the latest. RESOLVE and CONVERGE kick off this quarter. Once 2026 ends, we'll hold 2 real-world evidence datasets, which is a strong basis for expanding payer coverage as well as for boosting prescriber confidence. Third, we're growing in a disciplined way. Roughly $12 million in operating spend for Q1 shows deliberate investment in the resources required to succeed in our market, and we're expanding with great care. Guidance for the full year 2026 stays at $54 million-$58 million. We're still on course to reach operating profitability in 2027. Fourth, our organization has never been stronger. Our entire field team is set; we've brought in significant payer and marketing expertise. We've reinforced our board. We're constructing this company to win. We're eager about the rest of 2026, our near-term catalyst pipeline, BEACON data, CONVERGE data, both in Q3, sublingual PK data in Q3, further ex-U.S. milestones that will progress and continuing payer advancement. Each of these gives us encouraging signals that the platform we built for ZUNVEYL will keep producing rewards. Operator, with that said, we'll now take questions.

Executive executive
#6

Appreciate you taking the question. Jan here, filling in for Ram. Got a few things to ask. To start with, could you let me know whether anything significant has shifted regarding prior authorizations or step edit requirements during the last several months?

Lauren D'Angelo executive
#7

Absolutely, and I appreciate you raising that. From what we can tell, the volume of prior authorizations hasn't really moved up or down in any meaningful way since we launched. The thing that has shifted is how often we're getting approvals. Thanks to the extra support our reimbursement group provides, along with the know-how we've built up over the last 12 months, we've figured out what's needed to secure a prior authorization approval. You'll notice we cite 89%, though at times it runs above that, as our approval rate on those prior authorizations. And no, we really haven't encountered any significant restrictions being imposed when it comes to step edits or prior authorizations. My sense is that it's been fairly steady across the past three quarters.

Executive executive
#8

Understood; moving on to what I'd like to ask next — could you let me know whether any important feasibility milestones are expected to be hit as the film formulation is developed during the rest of 2026?

Michael McFadden executive
#9

Yes. That’s a wonderful question; we’re conducting a PK study that compares our sublingual formulation against our tablet formulation. If that data demonstrates equivalence, then we will file an IND with FDA for the sublingual program, which we think, if it gets approved, would bring us into the clinic, and we expect to deliver that IND in the latter part of the year.

Executive executive
#10

Thanks. If time permits, I’d like to ask one additional question. In the post-approval setting, how frequently should we expect data to come out from the ZUNVEYL clinical trials that are underway and those being planned?

Michael McFadden executive
#11

That's also a solid question. With BEACON, we're finishing up enrollment far sooner than we had expected. Our expectation had been that enrollment and top-line data would be reported in the latter portion of Q4; instead, enrollment wraps up during this quarter. The data still needs to be analyzed and our tables reviewed, and we expect to be in a position to put out top-line results for BEACON by early Q3 at the latest. That's well ahead of what was expected. What makes this study significant is that it's among the only datasets in long-term care — the segment we take part in — that is going to be published and carried out from a study standpoint. From the data, we should gain insights into ZUNVEYL's efficacy for cognition as well as behavioral response. It will provide us with tolerability data for ZUNVEYL, and it will also provide data on polypharmacy — the use, increase, or decrease of other agents when ZUNVEYL is utilized in therapy. This is a goldmine of data, and I expect there will be many publication opportunities coming out of BEACON. CONVERGE kicks off this quarter. Since it's a retrospective data analysis, the work will get done fairly efficiently, and we expect top-line data from CONVERGE to arrive in Q3 of 2026; our first segment of that data will be complete in Q3, with additional segments to follow. Every one of those datasets will be publishable, and we will be submitting for publication with both CONVERGE and BEACON. RESOLVE kicks off in Q2. Our expectation is not that RESOLVE will finish in 2026. It will finish in Q2 of 2027.

Executive executive
#12

Got it. Thank you so much.

Chase Knickerbocker analyst
#13

Good afternoon, and thanks for taking my questions. I have two, and I'll put both out there right away. You mentioned an acceleration in March. It would help to get a sense of how things trended across the quarter. Could you describe how much of that pickup you've carried into April? What do you believe was behind it in March, and what are you observing in April? Are your reps with less time on the job, for instance, becoming more productive? Second, your customer metrics appear to be expanding at roughly the same pace as volume on a sequential basis. How should we think about prescribing patterns getting deeper? Is there a cohort from recent quarters that's mature enough for us to track how the pattern plays out — say, someone prescribing for two or three quarters, and whether their prescribing gets deeper as time goes on? Thank you.

Lauren D'Angelo executive
#14

Absolutely. Both of those are excellent questions. I'll handle the first. March indeed stood as our largest month since launch, with the greatest volume of bottles dispensed, and that momentum is carrying into April. Looking at the core foundational pieces we've established, we finished expanding our sales force — the one that interacts with customers — and that effort concluded early in the current quarter. Our speakers are now set up, and we've carried out the speaker program; over on the payer side and the marketing side, we made a few tweaks to add extra strength before we head into the market. Day after day, things keep speeding up, and we anticipate that pickup will carry forward with really strong momentum. Regarding how we break the market into segments, that's exactly right; this has come up many times during the last year. Usually what happens is a provider gives the product a try. Within the long-term care community, these patients are extremely fragile, so they'll start with one or two of them; then comes a wait of one, two, occasionally three months to observe how the drug works, after which they'll put more patients on ZUNVEYL. Right now, we have a strong grasp of how adoption unfolds—specifically, the speed at which a doctor progresses from one tier into what you might call the loyalist group. The results we're observing are extremely encouraging. Our whole commercial organization is zeroed in on those physicians who've already given it a try, who have a handful of patients on therapy, so we can push them further along, and that is precisely the strategy we're using in the marketplace. We absolutely recognize this pattern. More and more prescribers keep entering that loyalist category, and we will keep carrying out our tactics while concentrating on that kind of segmentation. Whether that fully addresses what you were asking, I'm not sure — but that's more or less the way our tactics and our activity are actually being directed.

Chase Knickerbocker analyst
#15

That answers it. Appreciate it—really useful. Thanks for fielding the questions.

Dave Storms analyst
#16

Good evening, and thanks for answering my questions. Lauren, I'd like to begin, if I may, with that remark you made regarding AI analytics.

Lauren D'Angelo executive
#17

Of course.

Dave Storms analyst
#18

Could you share a bit more detail on how advanced this is, and perhaps any initial results so far?

Lauren D'Angelo executive
#19

Absolutely, and no question about it. From day one, Michael and I, along with the rest of our team, have genuinely worked to stay at the leading edge when it comes to what AI can do. Putting AI tools into practice isn't particularly difficult in the current landscape. In fact, we've already begun deploying them throughout the organization — not only on the commercial side, but truly company-wide. A large share of our people rely on AI every single day. When it comes to our commercial prospects — the way we go after the market, the way we break the market into segments — that's genuinely where we're putting these AI tools to work. As you'd expect, we have an enormous amount of data flowing in constantly, day after day, and those tools let us sort out the critical insights we need so we can then go after the market with an extremely precise strategy. We've applied it everywhere from a targeting standpoint. We've applied it everywhere from a segmentation standpoint. We lean on it every day simply to operate more efficiently on the administrative side throughout the whole team. We've truly reached that point. We're not fully there — meaning, I'd describe us as not 100% AI — but we have certainly, in all likelihood, embraced AI, and we're using it to be more efficient, more targeted, to ensure we're reaching the correct customers, and to ensure the correct message lands with the correct customer. My honest view is that we're actually well ahead of the majority of companies when it comes to our AI technical capabilities.

Dave Storms analyst
#20

Got it, thanks. Perhaps one brief modeling question too. Regarding that R&D note about Q2 coming in somewhat elevated — is it reasonable to think this builds up alongside the studies as the year goes on? Or are there any factors that could make things a bit more uneven?

Michael McFadden executive
#21

Right, I believe that will hinge on how the Resolve trial enrollment goes. In 2026, Resolve accounts for the bulk of what we're putting into R&D; the first patient is getting underway in Q2; come Q3 and Q4 we ought to witness a degree of acceleration. The natural assumption, David, would be that this happens further out, but a substantial number of sites are going to be un-enrolling during Q3, so how quickly they start bringing patients on board is what matters. There may be a slight bump — Q3 and Q4 could bring some bumpiness.

Dave Storms analyst
#22

Alright, that answers everything. Could I ask just one additional thing, Michael? During your prepared comments, you brought up a fresh TBI patent. I realize this is a long-term effort on your end, but is there anything further you could share with us at this point regarding what the outlook looks like for that channel?

Michael McFadden executive
#23

No, this represents a tremendously thrilling chance for our business. A $14 billion market possibility. It impacts patients starting in their teenage years right through to 65; that's where most of the patients are found, spanning every patient age range. There is no approved product for treating TBI, and nothing off-label is really being used that actually works against the cognitive impairment showing up in roughly one-half of concussion or TBI patients. Our early phase data has us genuinely enthusiastic. We'll be rolling that out during this year. The fact that our drug showed meaningful cognitive effects, neurogenesis, a reduction in inflammation, mobility improvements, and so on; that data is really strong pre-clinical data. You know, we'll find out whether it carries over into the clinic, and what has us most eager is pushing that program forward. On the clinical side, the next steps involve our plan to use the sublingual formulation for TBI. We've had a meeting with the agency regarding the pre-IND program, and we will conduct a tox study, a 12-week tox study, this year; we think that covers all the pre-clinical work required for that program to move an IND forward, which would take us into the clinic.

Dave Storms analyst
#24

That's great. Many thanks.

Michael McFadden executive
#25

Thanks, operator. I appreciate all of you for being with us this afternoon. It feels to us that this company is delivering — through our KPIs, through the clinical study know-how that backs our payers and healthcare professionals — and we'd urge everyone to keep watching the firm as it keeps delivering in Q2. Should anyone on this call, or anyone reading the transcript, have questions, don't hesitate to contact our IR group, and we'll gladly take any follow-ups that come out of this call. Thanks for being here.

Operator operator
#26

Everyone, we appreciate you joining. That brings today's teleconference to a close. Please feel free to hang up your lines, and enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Alpha Cognition Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Alpha Cognition Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.